A case series of hydroxychloroquine exacerbating the dermatomyositis rash
Dermatol Online J. 2023 Oct 15;29(5). doi: 10.5070/D329562407.ABSTRACTHydroxychloroquine (HCQ) is an antimalarial agent that is commonly used in the management of rheumatic skin disease. Few reports exist documenting exacerbation of dermatomyositis (DM) related to HCQ. Herein, we describe three adult patients with worsening DM cutaneous disease after starting HCQ and resolution or improvement with cessation. The time to exacerbation ranged from two weeks to nine months after the initiation of HCQ 400mg/day. Two of the three patients had antibodies to transcription intermediary factor 1γ (TIF1γ) and the other had antibodi...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Katelyn Rypka Michele Buonomo Connor Buechler Molly Benolken Adam Swigost Nikifor Konstantinov Kevin Gaddis Noah Goldfarb Source Type: research
A case series of hydroxychloroquine exacerbating the dermatomyositis rash
Dermatol Online J. 2023 Oct 15;29(5). doi: 10.5070/D329562407.ABSTRACTHydroxychloroquine (HCQ) is an antimalarial agent that is commonly used in the management of rheumatic skin disease. Few reports exist documenting exacerbation of dermatomyositis (DM) related to HCQ. Herein, we describe three adult patients with worsening DM cutaneous disease after starting HCQ and resolution or improvement with cessation. The time to exacerbation ranged from two weeks to nine months after the initiation of HCQ 400mg/day. Two of the three patients had antibodies to transcription intermediary factor 1γ (TIF1γ) and the other had antibodi...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Katelyn Rypka Michele Buonomo Connor Buechler Molly Benolken Adam Swigost Nikifor Konstantinov Kevin Gaddis Noah Goldfarb Source Type: research
A case series of hydroxychloroquine exacerbating the dermatomyositis rash
Dermatol Online J. 2023 Oct 15;29(5). doi: 10.5070/D329562407.ABSTRACTHydroxychloroquine (HCQ) is an antimalarial agent that is commonly used in the management of rheumatic skin disease. Few reports exist documenting exacerbation of dermatomyositis (DM) related to HCQ. Herein, we describe three adult patients with worsening DM cutaneous disease after starting HCQ and resolution or improvement with cessation. The time to exacerbation ranged from two weeks to nine months after the initiation of HCQ 400mg/day. Two of the three patients had antibodies to transcription intermediary factor 1γ (TIF1γ) and the other had antibodi...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Katelyn Rypka Michele Buonomo Connor Buechler Molly Benolken Adam Swigost Nikifor Konstantinov Kevin Gaddis Noah Goldfarb Source Type: research
A case series of hydroxychloroquine exacerbating the dermatomyositis rash
Dermatol Online J. 2023 Oct 15;29(5). doi: 10.5070/D329562407.ABSTRACTHydroxychloroquine (HCQ) is an antimalarial agent that is commonly used in the management of rheumatic skin disease. Few reports exist documenting exacerbation of dermatomyositis (DM) related to HCQ. Herein, we describe three adult patients with worsening DM cutaneous disease after starting HCQ and resolution or improvement with cessation. The time to exacerbation ranged from two weeks to nine months after the initiation of HCQ 400mg/day. Two of the three patients had antibodies to transcription intermediary factor 1γ (TIF1γ) and the other had antibodi...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Katelyn Rypka Michele Buonomo Connor Buechler Molly Benolken Adam Swigost Nikifor Konstantinov Kevin Gaddis Noah Goldfarb Source Type: research
A case series of hydroxychloroquine exacerbating the dermatomyositis rash
Dermatol Online J. 2023 Oct 15;29(5). doi: 10.5070/D329562407.ABSTRACTHydroxychloroquine (HCQ) is an antimalarial agent that is commonly used in the management of rheumatic skin disease. Few reports exist documenting exacerbation of dermatomyositis (DM) related to HCQ. Herein, we describe three adult patients with worsening DM cutaneous disease after starting HCQ and resolution or improvement with cessation. The time to exacerbation ranged from two weeks to nine months after the initiation of HCQ 400mg/day. Two of the three patients had antibodies to transcription intermediary factor 1γ (TIF1γ) and the other had antibodi...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Katelyn Rypka Michele Buonomo Connor Buechler Molly Benolken Adam Swigost Nikifor Konstantinov Kevin Gaddis Noah Goldfarb Source Type: research
A case series of hydroxychloroquine exacerbating the dermatomyositis rash
Dermatol Online J. 2023 Oct 15;29(5). doi: 10.5070/D329562407.ABSTRACTHydroxychloroquine (HCQ) is an antimalarial agent that is commonly used in the management of rheumatic skin disease. Few reports exist documenting exacerbation of dermatomyositis (DM) related to HCQ. Herein, we describe three adult patients with worsening DM cutaneous disease after starting HCQ and resolution or improvement with cessation. The time to exacerbation ranged from two weeks to nine months after the initiation of HCQ 400mg/day. Two of the three patients had antibodies to transcription intermediary factor 1γ (TIF1γ) and the other had antibodi...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Katelyn Rypka Michele Buonomo Connor Buechler Molly Benolken Adam Swigost Nikifor Konstantinov Kevin Gaddis Noah Goldfarb Source Type: research
A case series of hydroxychloroquine exacerbating the dermatomyositis rash
Dermatol Online J. 2023 Oct 15;29(5). doi: 10.5070/D329562407.ABSTRACTHydroxychloroquine (HCQ) is an antimalarial agent that is commonly used in the management of rheumatic skin disease. Few reports exist documenting exacerbation of dermatomyositis (DM) related to HCQ. Herein, we describe three adult patients with worsening DM cutaneous disease after starting HCQ and resolution or improvement with cessation. The time to exacerbation ranged from two weeks to nine months after the initiation of HCQ 400mg/day. Two of the three patients had antibodies to transcription intermediary factor 1γ (TIF1γ) and the other had antibodi...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Katelyn Rypka Michele Buonomo Connor Buechler Molly Benolken Adam Swigost Nikifor Konstantinov Kevin Gaddis Noah Goldfarb Source Type: research
A case series of hydroxychloroquine exacerbating the dermatomyositis rash
Dermatol Online J. 2023 Oct 15;29(5). doi: 10.5070/D329562407.ABSTRACTHydroxychloroquine (HCQ) is an antimalarial agent that is commonly used in the management of rheumatic skin disease. Few reports exist documenting exacerbation of dermatomyositis (DM) related to HCQ. Herein, we describe three adult patients with worsening DM cutaneous disease after starting HCQ and resolution or improvement with cessation. The time to exacerbation ranged from two weeks to nine months after the initiation of HCQ 400mg/day. Two of the three patients had antibodies to transcription intermediary factor 1γ (TIF1γ) and the other had antibodi...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Katelyn Rypka Michele Buonomo Connor Buechler Molly Benolken Adam Swigost Nikifor Konstantinov Kevin Gaddis Noah Goldfarb Source Type: research
A case series of hydroxychloroquine exacerbating the dermatomyositis rash
Dermatol Online J. 2023 Oct 15;29(5). doi: 10.5070/D329562407.ABSTRACTHydroxychloroquine (HCQ) is an antimalarial agent that is commonly used in the management of rheumatic skin disease. Few reports exist documenting exacerbation of dermatomyositis (DM) related to HCQ. Herein, we describe three adult patients with worsening DM cutaneous disease after starting HCQ and resolution or improvement with cessation. The time to exacerbation ranged from two weeks to nine months after the initiation of HCQ 400mg/day. Two of the three patients had antibodies to transcription intermediary factor 1γ (TIF1γ) and the other had antibodi...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Katelyn Rypka Michele Buonomo Connor Buechler Molly Benolken Adam Swigost Nikifor Konstantinov Kevin Gaddis Noah Goldfarb Source Type: research
Disease-associated immune cell endotypes in anti-MDA5-positive dermatomyositis using unbiased hierarchical clustering
ConclusionClustering analysis of peripheral immune cell profiles identified three different endotypes in MDA5+ dermatomyositis. Endotpye2 and 3 showed higher RPILD, 3-month mortality, pneumocystis jiroveci and CMV viremia. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - March 12, 2024 Category: Allergy & Immunology Source Type: research
Three cases of Anti-MDA5 positive dermatomyositis with interstitial lung disease and pneumomediastium
(Source: Dermatology Online Journal)
Source: Dermatology Online Journal - March 12, 2024 Category: Dermatology Authors: Figueiredo, Carolina Source Type: research
Intravenous cyclophosphamide therapy for patients with severe ocular inflammatory diseases who failed other immunomodulatory therapies
AbstractBackgroundOcular inflammatory diseases, including scleritis and uveitis, have been widely treated with immunomodulatory therapies (IMTs) as a steroid-sparing approach. Such strategy includes conventional therapies (antimetabolites, alkylating agents, and calcineurin inhibitors) as well as biologic agents like adalimumab, infliximab, rituximab, and tocilizumab. Cyclophosphamide (CP) is an alkylating agent and mainly inhibits the functioning of both T and B cells. Though known to have potential adverse events, including bone marrow suppression, hemorrhagic cystitis, and sterility, CP has been shown to be efficacious,...
Source: Journal of Ophthalmic Inflammation and Infection - March 11, 2024 Category: Opthalmology Source Type: research
ACR Image Competition 2023 Results, Part 4
For the 2023 Image Competition, the ACR sought images representing a diverse range of patients with idiopathic inflammatory myopathies (IIMs) or IIM mimics. Unilateral Heliotrope Rash in Anti-MDA-5 Antibody Dermatomyositis These images depict a 36-year-old patient with arthralgias, dyspnea and a unilateral heliotrope rash (image A). A unilateral heliotrope rash is a distinctive, but rare,... (Source: The Rheumatologist)
Source: The Rheumatologist - March 7, 2024 Category: Rheumatology Authors: Doron Rimar, MD Tags: Conditions Myositis anti-MDA-5 antibody dermatomyositis image case report Image Competition rash Source Type: research
A systematic review of primary large cell neuroendocrine carcinoma of the prostate
ConclusionLCNEC of the prostate is a rare disease that can occur de novo or transformation from prostatic adenocarcinoma. Most patients present at an advanced stage with poor prognosis and are treated with conventional chemotherapy regimens. Patients who had better outcomes were those who were diagnosed at an early stage and received treatment with surgery or radiation and androgen deprivation therapy (ADT). There was one case with an exceptional outcome that included a treatment regimen of M6620 and chemotherapy. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - March 7, 2024 Category: Cancer & Oncology Source Type: research
Acquired generalized lipodystrophy in a juvenile dermatomyositis patient
(Source: International Journal of Rheumatic Diseases)
Source: International Journal of Rheumatic Diseases - March 6, 2024 Category: Rheumatology Authors: Qiong Liu,
Meng Pan,
Hua Cao,
Jie Zheng,
Ye ‐ping Ruan,
Xiao‐qing Zhao Tags: LETTER TO THE EDITOR Source Type: research
